Astonea Labs Limited has completed its quarterly regulatory compliance by submitting the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The submission was made to BSE Limited on April 9, 2026, by Company Secretary and Compliance Officer Ankit Kapoor.

Compliance Certificate Details

The certificate was issued by KFIN Technologies Limited, serving as the company's Registrar and Share Transfer Agent (RTA). The document confirms adherence to regulatory provisions and provides transparency regarding the company's share dematerialization status during the quarter.

Share Dematerialization Status

The certificate provides important information about the company's share structure during the quarter. According to the RTA's confirmation, all shares of Astonea Labs Limited remained in dematerialized form throughout the quarter ended March 31, 2026. Significantly, no rematerialization requests were received during this period, indicating complete digital holding of the company's securities.

Regulatory Notifications

KFIN Technologies Limited has ensured comprehensive compliance by submitting the required certificates to multiple regulatory bodies and depositories:

• Central Depository Services (India) Limited (CDSL): Certificate submitted on April 1, 2026
• National Securities Depository Limited (NSDL): Certificate submitted on April 1, 2026
• Stock Exchanges: Details furnished to all exchanges where company shares are listed

KFIN Technologies Limited Role

As the appointed Registrar and Share Transfer Agent, KFIN Technologies Limited plays a crucial role in maintaining the company's shareholder records and ensuring regulatory compliance. The certificates were signed by senior officials including Dnyanesh Gharote (Vice President) and Sharmila Hemant Amin (Assistant Vice President), demonstrating proper authorization and oversight.

Compliance Significance

This quarterly submission represents part of Astonea Labs Limited's ongoing commitment to regulatory compliance and transparency. The Regulation 74(5) certificate ensures that all stakeholders, including investors and regulatory authorities, have access to accurate information about the company's share dematerialization activities and status.

Astonea Labs Limited has successfully completed the acquisition of a 25.74% equity stake in Damaira Pharmaceuticals Private Limited, utilizing ₹6.25 crore from its reallocated IPO proceeds. The transaction marks the completion of a strategic investment approved by shareholders at an Extraordinary General Meeting held on 27th March, 2026.

Acquisition Transaction Details

The company acquired 52,00,000 equity shares of Damaira Pharmaceuticals at an issue price of ₹12.02 per share, comprising a face value of ₹10.00 and a premium of ₹2.02. The acquisition was completed using funds from the variation in IPO objects, following comprehensive regulatory approvals and shareholder consent.

Target Company Profile

Damaira Pharmaceuticals Private Limited, incorporated on 29th July, 2020, operates in the pharmaceutical industry focusing on development, manufacturing, and trading of pharmaceutical products. The company has demonstrated significant growth trajectory with substantial revenue increases over recent years.

IPO Proceeds Reallocation Background

As of 26th February, 2026, Astonea Labs had unutilised IPO proceeds of ₹8,08,68,232 out of total IPO proceeds of ₹37,66,50,000. The reallocation of ₹6,25,00,000 constituted a 16.59% variation in the total IPO proceeds and received unanimous shareholder approval without any dissenting votes.

Strategic Investment Rationale

The acquisition aligns with Astonea Labs' strategic objectives to expand its footprint in the pharmaceutical sector and strengthen business operations. The investment is expected to create long-term value through synergies, including expansion into new product segments and markets, while enhancing the company's overall growth prospects.

Regulatory Compliance and Valuation

The transaction received comprehensive regulatory approvals through a structured process. Mr. Hitesh Jhamb of M/s Jhamb & Associates, an independent registered valuer, determined the fair value of equity shares based on the Net Asset Value method under the Cost Approach through a valuation report dated 11th March, 2026. The acquisition does not fall within related party transactions and was conducted on an arm's length basis.